Seydi OKUMUŞ, Şeniz DEMİRYÜREK, Mehtap ÖZKUR, Erol COŞKUN

No major impact of insertion/deletion polymorphism of the angiotensin-converting enzyme gene on thyroid-associated ophthalmopathy

To investigate the association between ACE gene I/D polymorphism and thyroid-associated ophthalmopathy (TO) in the Turkish population. Materials and methods: A total of 105 patients with TO and 102 healthy control subjects were enrolled in this case-control study. Genomic DNA was extracted from peripheral blood leukocytes, and I/D polymorphism of the ACE gene (ACE) was determined using a polymerase chain reaction. Results: There were no marked changes in allelic frequencies and genotype distribution of ACE I/D polymorphism between patients and control subjects. The distribution of I/D polymorphism and allele frequencies of TO patients were not significantly different from those of the controls: DD genotype 34.3% vs. 41.2%; ID genotype 46.7% vs. 43.1%; and II genotype 19.0% vs. 15.7%; D allele 57.6% vs. 62.7%; I allele 42.4% vs. 37.3% (P > 0.05). Genotype and allele frequencies for men and women were also similar between the groups. Conclusion: Our data suggest that ACE gene I/D polymorphism does not constitute a risk factor for TO in the Turkish population. Further studies using greater numbers of patients from different populations are required to clarify the role of the ACE gene in conferring susceptibility to TO.

Anahtar Kelimeler:

Key words: ACE gene, allele frequency, I/D genotype, polymorphism, thyroid-associated ophthalmopathy

No major impact of insertion/deletion polymorphism of the angiotensin-converting enzyme gene on thyroid-associated ophthalmopathy

Keywords:

Key words: ACE gene, allele frequency, I/D genotype, polymorphism, thyroid-associated ophthalmopathy,

PDF

___

Versura P, Campos EC. The ocular surface in thyroid diseases. Curr Opin Allergy Clin Immunol 2010; 10: 486–92.
Szyper-Kravitz M, Marai I, Shoenfeld Y. Coexistence of thyroid autoimmunity with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of autoimmunity. Autoimmunity 2005; 38: 247–55.
Hadj-Kacem H, Rebuffat S, Mnif-Féki M, Belguith-Maalej S, Ayadi H, Péraldi-Roux S. Autoimmune thyroid diseases: genetic susceptibility of thyroid-specific genes and thyroid autoantigens contributions. Int J Immunogenet 2009; 36: 85–96.
Karoutsou E, Polymeris A. Pathogenesis of Graves’ disease focusing on Graves’ ophthalmopathy. Endocr Regul 2011; 45: 209–20.
Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21: 168–99.
Crisan D, Carr J. Angiotensin I-converting enzyme: genotype and disease associations. J Mol Diagn 2000; 2: 105–15.
Carluccio M, Soccio M, De Caterina R. Aspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system. Eur J Clin Invest 2001; 31: 476–88.
Vaajanen A, Vapaatalo H. Local ocular renin-angiotensin system—a target for glaucoma therapy? Basic Clin Pharmacol Toxicol 2011; 109: 217–24.
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343–6.
Sagheb MM, Owji N, Moini M. Potential benefit of angiotensin converting enzyme inhibitors for hindering progression of Graves’ ophthalmopathy. Med Hypotheses 2008; 70: 895.
Werner SC. Modification of the classification of the eye changes of Graves’ disease. Am J Ophthalmol 1977; 83: 725–7.
Müllenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 1989; 5: 3
Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C et al. Contribution of genetic polymorphism in the reninangiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 1997; 99: 1585–95.
Rudnicki M, Mayer G. Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. Pharmacogenomics 2009; 10: 463–76.
Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol 2008; 3: 1511–25.
Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264: 224–36.
Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11: 155–62.
Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35: 881–900.
Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010; 362: 726–38.
Reiners C, Gramer-Kurz E, Pickert E, Schweisfurth H. Changes of serum angiotensin-I-converting enzyme in patients with thyroid disorders. Clin Physiol Biochem 1988; 6: 44–9.
Yalçın S, Ülger BV, Parlak Ö, Uçar AE, Sarıkaya SM, Özer M et al. The role of preoperative serum thyroglobulin and thyroid auto-antibody levels before histopathological diagnosis of thyroid cancers. Turk J Med Sci 2011; 41: 487–93.
Langham RG, Kelly DJ, Gow RM, Zhang Y, Cordonnier DJ, Pinel N et al. Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition. Diabetes Care 2006; 29: 2670–5.
Takahashi E, Nagano O, Ishimoto T, Yae T, Suzuki Y, Shinoda T et al. Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem 2010; 285: 4060–73.
Kızıltunç A, Başoğlu M, Avcı B, Çapoğlu İ. Serum IL-6 and TNF-a in patients with thyroid disorders. Turk J Med Sci 1999; 29: 25–9.
Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002; 12: 855–60.
Murphey LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensinconverting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 2000; 102: 829–32.
Samani NJ, Thompson JR, O’Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996; 94: 708–12.
Staessen JA, Ginocchio G, Wang JG, Saavedra AP, Soubrier F, Vlietinck R et al. Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. J Cardiovasc Risk 1997; 4: 401–22.
Berdeli A, Cam FS. Prevalence of the angiotensin I converting enzyme gene insertion/deletion polymorphism in a healthy Turkish population. Biochem Genet 2009; 47: 412–20.
Bayoglu B, Cengiz M, Karacetin G, Uysal O, Kocabasoğlu N, Bayar R et al. Genetic polymorphism of angiotensin I-converting enzyme (ACE), but not angiotensin II type I receptor (ATr1), has a gender-specific role in panic disorder. Psychiatry Clin Neurosci 2012; 66: 130–7.